clinical trial · NCT07504263
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
Advanced MalignanciesOncologyColorectal CancerPancreatic CancerCancerRP-001
brief summary
Phase 1/2a Study of RP-001 in participants with Advanced Malignancies
started
Apr 23, 2026
primary completion
Dec 1, 2027
completion
Apr 1, 2028
last updated
Mar 31, 2026
detailed description
An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of RP-001 in Participants with Advanced Malignancies
official title
An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of RP-001 in Participants With Advanced Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol